Prelude Therapeutics Inc. (PRLD) News
Filter PRLD News Items
PRLD News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PRLD News Highlights
- PRLD's 30 day story count now stands at 2.
- Over the past 13 days, the trend for PRLD's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- LNG, DEC and SHEL are the most mentioned tickers in articles about PRLD.
Latest PRLD News From Around the Web
Below are the latest news stories about PRELUDE THERAPEUTICS INC that investors may wish to consider to help them evaluate PRLD as an investment opportunity.
AI Meets Biotech: 3 Top Stocks Transforming Medical ScienceThe AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology. |
Prelude Therapeutics Announces $25 Million Private PlacementWILMINGTON, Del., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced a private placement that the Company estimates will result in gross proceeds of approximately $25 million before deducting estimated offering expenses payable by the Company. Proceeds from the private placement will be used to primarily fund the continued advancement of its SMARCA2 portfolio, for working ca |
Shell's (SHEL) Prelude LNG Facility to Restart in DecemberShell's (SHEL) Prelude LNG facility, nearing the completion of extensive maintenance, is poised for a strategic comeback, aiding the global LNG market. |
Prelude Therapeutics Insiders Are Down US$149k But Regain Some LossesInsiders who bought US$263.0k worth of Prelude Therapeutics Incorporated ( NASDAQ:PRLD ) stock in the last year have... |
Q3 2023 Abcellera Biologics Inc Earnings CallQ3 2023 Abcellera Biologics Inc Earnings Call |
Prelude Therapeutics Inc (PRLD) Reports Q3 Financial Results and Strategic Pipeline ProgressCompany prioritizes SMARCA2 degrader and CDK9 inhibitor programs, reports cash runway into 2026 |
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial ResultsPrioritization of its first-in-class SMARCA2 degrader and potentially best-in-class CDK9 inhibitor programs for continued clinical development Enters partnership with AbCellera to develop a portfolio of precision ADCs with first program being a SMARCA degrader-antibody conjugate Cash runway into 2026 with $230.5 million of cash, cash equivalents and marketable securities WILMINGTON, Del., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-sta |
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in OncologyWILMINGTON, Del. & VANCOUVER, British Columbia, November 01, 2023--Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology |
Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International ConferenceWILMINGTON, Del. and BOSTON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a clinical-stage precision oncology company, announces multiple clinical and preclinical posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, known as the Triple Meeting, from October 11 - 15, 2023 at the Hynes Convesntion Center in Boston, MA. The four Prelude poster presentations include data from two ongoing Phase 1 clinic |
All You Need to Know About Prelude Therapeutics Incorporated (PRLD) Rating Upgrade to BuyPrelude Therapeutics Incorporated (PRLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |